Shingles Vaccine May Reduce Cardiovascular Disease Risk by 9%

Recent research shows that the shingles vaccine may help reduce the risk of cardiovascular disease. A boy and the sea · E+/Getty A recent study found that the recombinant shingles vaccine (Shingrix) was associated with a 9% lower cardiovascular disease burden compared with the older live vaccine. Researchers observed lower burdens of coronary heart disease, heart failure, ischemic stroke in men, and atrial fibrillation (AFib) among those who received Shingrix. The CDC recommends the shingles vaccine for all adults ages 50 and older, as well as adults ages 19 and older who are or will be immunocompromised. The recombinant shingles vaccine (Shingrix) may reduce the burden of cardiovascular disease compared with the older live vaccine (Zostavax), according to a study published in Nature Medicine on August 26. The United States began transitioning from Zostavax to Shingrix in 2017, and Zostavax was discontinued in the United States in 2020. The researchers noted that previous studies compared people who had the Shingrix vaccine to those who were unvaccinated. This study compared individuals who had received the Shingrix vaccine with those who had received Zostavax before its discontin…

≈